Tacrolimus/Methotrexate versus Cyclosporine/Methotrexate as Graft-versus-Host Disease Prophylaxis in Patients with Severe Aplastic Anemia Who Received Bone Marrow Transplantation from Unrelated Donors: Results of Matched Pair Analysis

Hiroshi Yagasaki, Seiji Kojima, Hiromasa Yabe, Koji Kato, Hisato Kigasawa, Hisashi Sakamaki, Masahiro Tsuchida, Shunichi Kato, Takakaza Kawase, Hideki Muramatsu, Yasuo Morishima, Yoshihisa Kodera

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Tacrolimus (FK) and cyclosporine (CsA) have been shown to be effective in the prophylaxis of graft-versus-host disease (GVHD). However, no comparative studies have yet been conducted to examine the efficacy of FK/methotrexate (MTX) and CsA/MTX in patients with severe aplastic anemia (SAA) given unrelated donor bone marrow transplantation (U-BMT). We used matched-pair analysis to compare FK/MTX with CsA/MTX in patients with SAA who received U-BMT through the Japan Marrow Donor Program. Forty-seven pairs could be matched exactly for recipient age and conditioning regimens. Forty-five patients achieved engraftment in the FK group and 42 patients in the CsA group. The probability of grade II-IV acute GVHD (aGVHD) was 28.9% in the FK group and 32.6% in the CsA group (P = .558). The probability of chronic GVHD (cGVHD) was 13.3% in the FK group and 36.0% in the CsA group (P = .104). The 5-year survival rate was 82.8% in the FK group and 49.5% in the CsA group (P = .012). The study shows the superiority of FK/MTX over CsA/MTX in overall survival because of the lower incidence of transplantation-related deaths. A prospective randomized study comparing FK/MTX and CsA/MTX is warranted.

Original languageEnglish
Pages (from-to)1603-1608
Number of pages6
JournalBiology of Blood and Marrow Transplantation
Volume15
Issue number12
DOIs
Publication statusPublished - Dec 1 2009
Externally publishedYes

Fingerprint

Matched-Pair Analysis
Unrelated Donors
Aplastic Anemia
Tacrolimus
Graft vs Host Disease
Bone Marrow Transplantation
Methotrexate
Cyclosporine
Japan
Survival Rate
Transplantation
Bone Marrow
Tissue Donors
Prospective Studies
Survival
Incidence

All Science Journal Classification (ASJC) codes

  • Hematology
  • Transplantation

Cite this

Tacrolimus/Methotrexate versus Cyclosporine/Methotrexate as Graft-versus-Host Disease Prophylaxis in Patients with Severe Aplastic Anemia Who Received Bone Marrow Transplantation from Unrelated Donors : Results of Matched Pair Analysis. / Yagasaki, Hiroshi; Kojima, Seiji; Yabe, Hiromasa; Kato, Koji; Kigasawa, Hisato; Sakamaki, Hisashi; Tsuchida, Masahiro; Kato, Shunichi; Kawase, Takakaza; Muramatsu, Hideki; Morishima, Yasuo; Kodera, Yoshihisa.

In: Biology of Blood and Marrow Transplantation, Vol. 15, No. 12, 01.12.2009, p. 1603-1608.

Research output: Contribution to journalArticle

Yagasaki, Hiroshi ; Kojima, Seiji ; Yabe, Hiromasa ; Kato, Koji ; Kigasawa, Hisato ; Sakamaki, Hisashi ; Tsuchida, Masahiro ; Kato, Shunichi ; Kawase, Takakaza ; Muramatsu, Hideki ; Morishima, Yasuo ; Kodera, Yoshihisa. / Tacrolimus/Methotrexate versus Cyclosporine/Methotrexate as Graft-versus-Host Disease Prophylaxis in Patients with Severe Aplastic Anemia Who Received Bone Marrow Transplantation from Unrelated Donors : Results of Matched Pair Analysis. In: Biology of Blood and Marrow Transplantation. 2009 ; Vol. 15, No. 12. pp. 1603-1608.
@article{fdc11455219044d8949af18fe3caa0d6,
title = "Tacrolimus/Methotrexate versus Cyclosporine/Methotrexate as Graft-versus-Host Disease Prophylaxis in Patients with Severe Aplastic Anemia Who Received Bone Marrow Transplantation from Unrelated Donors: Results of Matched Pair Analysis",
abstract = "Tacrolimus (FK) and cyclosporine (CsA) have been shown to be effective in the prophylaxis of graft-versus-host disease (GVHD). However, no comparative studies have yet been conducted to examine the efficacy of FK/methotrexate (MTX) and CsA/MTX in patients with severe aplastic anemia (SAA) given unrelated donor bone marrow transplantation (U-BMT). We used matched-pair analysis to compare FK/MTX with CsA/MTX in patients with SAA who received U-BMT through the Japan Marrow Donor Program. Forty-seven pairs could be matched exactly for recipient age and conditioning regimens. Forty-five patients achieved engraftment in the FK group and 42 patients in the CsA group. The probability of grade II-IV acute GVHD (aGVHD) was 28.9{\%} in the FK group and 32.6{\%} in the CsA group (P = .558). The probability of chronic GVHD (cGVHD) was 13.3{\%} in the FK group and 36.0{\%} in the CsA group (P = .104). The 5-year survival rate was 82.8{\%} in the FK group and 49.5{\%} in the CsA group (P = .012). The study shows the superiority of FK/MTX over CsA/MTX in overall survival because of the lower incidence of transplantation-related deaths. A prospective randomized study comparing FK/MTX and CsA/MTX is warranted.",
author = "Hiroshi Yagasaki and Seiji Kojima and Hiromasa Yabe and Koji Kato and Hisato Kigasawa and Hisashi Sakamaki and Masahiro Tsuchida and Shunichi Kato and Takakaza Kawase and Hideki Muramatsu and Yasuo Morishima and Yoshihisa Kodera",
year = "2009",
month = "12",
day = "1",
doi = "10.1016/j.bbmt.2009.08.012",
language = "English",
volume = "15",
pages = "1603--1608",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "12",

}

TY - JOUR

T1 - Tacrolimus/Methotrexate versus Cyclosporine/Methotrexate as Graft-versus-Host Disease Prophylaxis in Patients with Severe Aplastic Anemia Who Received Bone Marrow Transplantation from Unrelated Donors

T2 - Results of Matched Pair Analysis

AU - Yagasaki, Hiroshi

AU - Kojima, Seiji

AU - Yabe, Hiromasa

AU - Kato, Koji

AU - Kigasawa, Hisato

AU - Sakamaki, Hisashi

AU - Tsuchida, Masahiro

AU - Kato, Shunichi

AU - Kawase, Takakaza

AU - Muramatsu, Hideki

AU - Morishima, Yasuo

AU - Kodera, Yoshihisa

PY - 2009/12/1

Y1 - 2009/12/1

N2 - Tacrolimus (FK) and cyclosporine (CsA) have been shown to be effective in the prophylaxis of graft-versus-host disease (GVHD). However, no comparative studies have yet been conducted to examine the efficacy of FK/methotrexate (MTX) and CsA/MTX in patients with severe aplastic anemia (SAA) given unrelated donor bone marrow transplantation (U-BMT). We used matched-pair analysis to compare FK/MTX with CsA/MTX in patients with SAA who received U-BMT through the Japan Marrow Donor Program. Forty-seven pairs could be matched exactly for recipient age and conditioning regimens. Forty-five patients achieved engraftment in the FK group and 42 patients in the CsA group. The probability of grade II-IV acute GVHD (aGVHD) was 28.9% in the FK group and 32.6% in the CsA group (P = .558). The probability of chronic GVHD (cGVHD) was 13.3% in the FK group and 36.0% in the CsA group (P = .104). The 5-year survival rate was 82.8% in the FK group and 49.5% in the CsA group (P = .012). The study shows the superiority of FK/MTX over CsA/MTX in overall survival because of the lower incidence of transplantation-related deaths. A prospective randomized study comparing FK/MTX and CsA/MTX is warranted.

AB - Tacrolimus (FK) and cyclosporine (CsA) have been shown to be effective in the prophylaxis of graft-versus-host disease (GVHD). However, no comparative studies have yet been conducted to examine the efficacy of FK/methotrexate (MTX) and CsA/MTX in patients with severe aplastic anemia (SAA) given unrelated donor bone marrow transplantation (U-BMT). We used matched-pair analysis to compare FK/MTX with CsA/MTX in patients with SAA who received U-BMT through the Japan Marrow Donor Program. Forty-seven pairs could be matched exactly for recipient age and conditioning regimens. Forty-five patients achieved engraftment in the FK group and 42 patients in the CsA group. The probability of grade II-IV acute GVHD (aGVHD) was 28.9% in the FK group and 32.6% in the CsA group (P = .558). The probability of chronic GVHD (cGVHD) was 13.3% in the FK group and 36.0% in the CsA group (P = .104). The 5-year survival rate was 82.8% in the FK group and 49.5% in the CsA group (P = .012). The study shows the superiority of FK/MTX over CsA/MTX in overall survival because of the lower incidence of transplantation-related deaths. A prospective randomized study comparing FK/MTX and CsA/MTX is warranted.

UR - http://www.scopus.com/inward/record.url?scp=70350569966&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350569966&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2009.08.012

DO - 10.1016/j.bbmt.2009.08.012

M3 - Article

C2 - 19896085

AN - SCOPUS:70350569966

VL - 15

SP - 1603

EP - 1608

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 12

ER -